Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Toshifumi TadaTakashi KumadaAtsushi HiraokaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataFujimasa TadaHideko OhamaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiHisashi KosakaAtsushi NaganumaTomomitsu MatonoTomoko AokiHidekatsu KurodaYutaka YataYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaMasatoshi Kudonull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
The use of Atezo/Bev as first-line systemic therapy in patients with BCLC-B HCC is expected to result in good PFS.